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Abstract
Background: Meta-analysis typically involves combining the estimates from independent studies in order to
estimate a parameter of interest across a population of studies. However, outliers often occur even under the
random effects model. The presence of such outliers could substantially alter the conclusions in a meta-analysis.
This paper proposes a methodology for identifying and, if desired, downweighting studies that do not appear
representative of the population they are thought to represent under the random effects model.
Methods: An outlier is taken as an observation (study result) with an inflated random effect variance. We used the
likelihood ratio test statistic as an objective measure for determining whether observations have inflated variance
and are therefore considered outliers. A parametric bootstrap procedure was used to obtain the sampling
distribution of the likelihood ratio test statistics and to account for multiple testing. Our methods were applied to
three illustrative and contrasting meta-analytic data sets.
Results: For the three meta-analytic data sets our methods gave robust inferences when the identified outliers
were downweighted.
Conclusions: The proposed methodology provides a means to identify and, if desired, downweight outliers in
meta-analysis. It does not eliminate them from the analysis however and we consider the proposed approach
preferable to simply removing any or all apparently outlying results. We do not however propose that our
methods in any way replace or diminish the standard random effects methodology that has proved so useful,
rather they are helpful when used in conjunction with the random effects model.
Background
Meta-analysis typically involves combining summary
information from related but independent studies in
order to estimate an overall treatment effect. One pro-
blem in meta-analysis concerns the presence of outlying
studies whose results can excessively influence para-
meter estimates. If some results appear unusual then it
is of course appropriate to check these for errors; in
particular if estimates and standard errors of treatment
effects have been confused with other quantities then
the results from the meta-analysis will be erroneous. We
assume here that despite the careful cleaning of data,
some study results still appear unusual and are
considered potential outliers. In some instances, the
identification and understanding of the reason for unu-
sual study results can in itself lead to further under-
standing of the subject area. With the usual meta-
analysis aim of estimating the overall treatment effect in
mind, if a small proportion of studies are not in fact
truly representative of the population of interest for
some unknown reason then their inclusion in the analy-
sis can have unfortunate implications for the resulting
inferences. In order to address this type of issue, the
Cochrane Collaboration have developed their Risk of
Bias tool [1]. This tool enables the identification of
studies which have been conducted differently, and in
particularly poorly, and provides a means to explain
some unusual findings. This type of exercise, which
looks for possible reasons for any unusual results, is
highly recommended when performing meta-analyses.
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Related investigations, which might identify unusual
patient populations or study practices, are another way
to explain the presence of study results which appear
strange if taken at face value.
Despite the usefulness of such investigations, it is
sometimes the case that some study results are apparent
outliers whose cause is unclear. In such instances there
is the natural concern that if these study results are
included in the analysis but they are not truly represen-
tative of the population of interest then misleading
inference is almost inevitable. Excluding trial results
based on their findings is another source of bias how-
ever and the presence of unexplained and unusual study
results places the statistician in an uncomfortable situa-
tion. Outliers in regression analysis have been widely
researched [2,3], but research into outliers in meta-ana-
lysis is much more recent [4,5]. If any outliers contri-
bute very little weight to the analysis, because the
studies that provide them are small for example, the
choice between their inclusion or exclusion is moot;
‘outlier’ is not synonymous with ‘influential’. Large stu-
dies are inevitably very influential but need not be out-
liers, for example. However outlying results are prone to
be influential and their presence immediately raises
further issues and concerns about any formal statistical
inference that might be attempted.
In this paper we propose a random effects variance
shift outlier model (RVSOM). This model initially allows
the identification of any apparent outliers under the
standard random effects model for meta-analysis. This
approach is useful because the identification of outliers
is in itself problematic. For example, a very large study
may initially appear consistent with the rest of the data,
but on closer inspection it might provide an estimate
much further from the pooled estimate than we expect
by chance. Under such circumstances, it may be that
this study is an outlier, rather than a smaller study with
a more extreme point estimate, which might at first
glance be a more obvious candidate.
If any study or studies are identified as outliers, then
the RVSOM model further allows their downweighting.
The extent of this downweighting depends on how unu-
sual the outliers appear to be, and takes into account
the studies’ estimated treatment effect and the variance
structure. This approach can be used to complement
the more usual random effects analysis as a secondary
or sensitivity analysis and we consider this approach
more satisfactory than performing analyses that simply
omit any outliers although these analyses may also be
performed if desired. The model underlying the
RVSOM was also considered by [6] in the context of
outliers in the linear mixed model. Gumedze et al. [6]
presented a model for accommodating outliers as
observations with inflated variance, an outlier being
indicated by the size of the associated shift in the var-
iance. The RVSOM differs in that it down-weights
observations in the presence of the random effects
model for meta-analysis which has the residual variance
matrix regarded as known when pooling the studies’
results.
The paper is set out as follows. Firstly, we present a
random effects variance shift outlier model RVSOM
for the random effects model for meta-analytic data.
Secondly, we show how this model may be used in
practice. In particular, we propose a parametric boot-
strap procedure to generate the empirical distribution
of the resulting likelihood ratio test statistics and to
account for multiple testing using these statistics. The
proposed approach is then applied to three meta-ana-
lytic data sets, two of which come from the Cochrane
Collaboration. Finally, we conclude the paper with a
discussion.
Methods
A RVSOM in meta-analysis
The standard random effects model
We base our modelling on the standard random effects
model [7-10] for meta-analysis,
y u e= + +1n , (1)
where y is a n-vector of estimated treatment effects for
the n independent studies, μ is the unknown overall
treatment effect, 1n is a n-vector of ones, u is a n-vector
of unknown random effects, u ~ N(0, τ2In) where τ
2 is
the between-study variance which is unknown. e repre-
sents residual errors with e ~ N(0, R), where
R = diag n( , ,..., )  12 22 2 . The elements of R, the study
variances, are regarded as known [8], although in reality
they are estimated from the n independent studies using
standard methods. The variance-covariance matrix of (1)
can then be written as
var( ) ,y V I R= = + 2 n (2)
with the variance of the ith study treatment effect
given as var( )yi i= + 2 2 .
We will obtain inferences using restricted maximum
likelihood estimation (REML). This is a standard approach
in the context of meta-analysis [10] and by using a likeli-
hood based approach we can easily fit models with the
flexible variance structure we require. We use restricted
maximum likelihood rather than the maximum likelihood
because we wish to avoid the underestimation of τ2; any
underestimation of the between-study variance might
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unnecessarily exacerbate the appearance of unusual and
hence outlying results. The REML log-likelihood function
for model (1) is [10]
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The associated REML estimate of the between-study
variance parameter from this model is denoted ˆ 2 . In
general, there is no analytic form for this estimate and it
is obtained by using an iterative algorithm which maxi-
mises (3) numerically. Several statistical software
packages are available for fitting the model (1) such as
GenStat [11], R [12], SAS [13] and STATA [14]. Model
(1) has the form of a variance components model and
can also be fitted with any statistical software that allows
for fitting the appropriate linear mixed model with R
mixed and τ2 estimated from the data [10]. If ˆ 2 0=
then the random effects model collapses to a fixed
effects model. Upon approximating τ2 with ˆ 2 , infer-
ences for the treatment effect are easily obtained in the
standard way [9] but this standard procedure requires a
reasonably large sample size to perform well in practice
[15].
Extending the random effects model to the RVSOM
The random effects variance shift outlier model
(RVSOM) for the jth study (which allows an inflated
variance for the jth study) takes takes the form
y d u e= + + + 1n j j , (4)
which adds an extra term δj dj to model (1), where dj
is the jth unit vector of length n, i.e. with value 1 in the
jth position and zero elsewhere, and δj is an unknown
random coefficient with  j jN ( , )0 2 for  j2 0≥ .
The subscript j indicates which study has an inflated
variance. Model (4) has the form of a simple linear
mixed model with δj as a random effect with variance
 j2 . The variance-covariance matrix for the data under
the RVSOM (4) for the jth observation is
var( )y d d V= ′ + j j2 j .
If we further define i2 0= for i ≠ j, the REML log-
likelihood function for this model is
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is the estimate of μ from model (4). The REML log-
likelihood function is now a function of both τ2 and
 j2 , so there are two parameters to estimate under the
RVSOM for the jth observation from the restricted log-
likelihood. As for the random effects model, once the
variance structure has been estimated inference for the
treatment effect is straightforward because the study
variances are regarded as fixed and known when pooling
the studies’ results.
The random effects model assumes that the studies’
treatment effects are normally distributed and
exchangeable. This exchangeability assumption is cru-
cial for the identification of the RVSOM. If instead, for
example, fixed effects were used for u then w j
2 would
not be identifiable. Only one study contributes a term
involving w j
2 to the full likelihood. We can therefore
expect w j
2 to be weakly identified and so rather than
use the RVSOM for the primary analysis, we advocate
its use to identify outliers and in the context of a sen-
sitivity analysis. We assess whether there is evidence
that w j
2 is greater than zero for a particular study
using a parametric bootstrap procedure below, where
we produce the replications under the fitted random
effects model. If a confidence interval for w j
2 was
required then this could be obtained by modifying this
procedure, so that the bootstrap replications were pro-
duced using the fitted RVSOM, and obtaining the con-
fidence interval from the resulting distribution’s
percentiles. The normality assumption for δj is made
for relative simplicity, because some distributional
assumption is needed to make progress and it is a nat-
ural assumption to make, but it would be of interest to
investigate how sensitive our procedure is to this
assumption.
A RVSOM for observation j provides an estimate of
the shift in the error variance associated with that obser-
vation. A large shift may indicate a possible outlier and
can be used to down-weight the observation(s) if
required. However, an objective measure to indicate this
down-weighting needed, which we provide in the next
section.
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An extension of model (4) which allows different
inflated variances for more than one study can be writ-
ten as
y D u eI I= + + +1n  ,
where I is a subset {1, 2,..., r} of studies considered to
be outliers, D = [dj] is an n × r matrix containing
entires of 0 and 1, where an entry of 1 in the ith row
and jth column indicates that study i has the jth of r
inflated variances, and δI is a r × 1 vector of unknown
random effects. We refer to this model as an ‘extended
RVSOM’.
Implementation of the RVSOM
Having fitted the random effects model and made the
usual inferences, there may be the concern that outliers
are present and that these might have unfortunate
implications for the resulting inferences. We then sug-
gest initially fitting the RVSOM to each observation in
turn. If a large ˆ j2 is obtained when fitting the RVSOM
to the jth observation then the size of ˆ j2 may indicate
that this observation is an outlier. We therefore need to
determine what constitutes a large w j
2 in relation to the
size of the study and the other variance components.
We consider the use of the likelihood ratio test (LRT)
to evaluate the null hypothesis H j0
2 0: = against the
alternative HA j j( ) : 2 0> for a RVSOM for observation
j (4). The standard LRT statistic provides a means to
test this hypothesis and takes the form
LRT RL RLj j j= −{ }2 2 2 2( ; ) ( , ; ) .( )  y y (5)
The LRT statistic is analytically intractable except in
special cases, but readily obtained from standard mixed
model software. Although the restricted log-likelihood is
suitable for constructing likelihood ratio tests for var-
iance components provided the mean structure of the
null and alternative models are the same [16], the stan-
dard asymptotic theory which relates the distribution of
LRT statistic to a c2 distribution under the null does
not apply here. This is because the null hypothesis falls
on the boundary of the parameter space and regularity
conditions are not met [17]. Stram and Lee [18,19]
showed that the asymptotic null distribution of the LRT
for testing this type of hypothesis is a 50:50 mixture of
two chi-squared distributions on zero and one degree of
freedom. However, their results assumed either that the
data values were independent and identically distributed,
or that the data set could be partitioned into a number
of independent subsets such that the number of subsets
increased with the size of the data set [20]. For a
RVSOM model, these conditions cannot be met, as the
variance shift applies to a single observation and we
encounter all the issues associated with multiple testing.
Following Gumedze et al. [6], we use a parametric boot-
strap procedure to obtain the distributions of the LRT
statistics (5).
Empirical distribution of the LRT statistic and multiple
testing
We propose the following parametric bootstrap proce-
dure to obtain empirical distribution of the likelihood
ratio test statistics under the null hypothesis that no
outliers are present in the data.
Step 1: Fit the null model defined by (1) to the data to
obtain estimates ˆ and ˆ 2 .
Step 2a: Generate a new data vector
y u e* * *^ ,= + +1n
where u* is randomly generated as N( , )0 ^2In , and
e* is randomly generated as N(0, R). Fit the null model
to y*.
Step 2b: Compute the likelihood ratio test statistics
LRTj, j = 1,..., n, by fitting the RVSOM (4) to the simu-
lated data y* for each observation in turn and compute
and save the order statistics of the set {LRTj; j = 1... n}.
Step 3: Repeat steps 2a and 2b R times, for R reason-
ably large, for example R = 5000. This step generates
the bootstrap replications and hence an empirical distri-
bution of size R for each order statistic.
Step 4: Calculate the 100(1-a)th percentile for each
order statistic for the required significance level a. The
percentiles using a = 0.05 and for the k = 1 (largest
LRT statistic), k = 2 (second largest LRT statistic) and
k = 3 order statistics are shown in the plots given in
next section. These percentiles provide thresholds for
assessing whether up to three studies are outliers under
the random effects model.
Identifying and downweighting outliers
Using any significance level alpha for the LRT order sta-
tistics, the presence of outliers can be formally assessed
by placing the LRT statistics in descending order and
regarding any set of r studies that provide the largest
LRT statistics and reach the corresponding threshold
are regarded as outliers. Since our method has identified
these studies’ findings as being unusual, it is pertinent
to check the conduct and protocols of these trials care-
fully to see if any explanation can be found for their
apparently outlying results.
If there is no apparent reason to exclude these trials,
perhaps from the Cochrane Risk of Bias tool for exam-
ple, then the concern that they might be unduly influen-
tial but excludable on some unforseen grounds persists.
In such circumstances a simple approach is to consider
sensitivity analyses where some or all of these trials are
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excluded but simply discarding entire trials is rather
extreme and various combinations of exclusions might
be contemplated in this procedure. Instead of this dele-
tion of observations we propose fitting an ‘extended
RVSOM’ where separate and additional variance compo-
nents  j2 0≥ are allowed for all of the outlying trials.
Since these additional variances cannot be negative, the
extra variability permitted by this model downweights
the apparent outliers, where this downweighting
depends on how unusual their results appear to be. If
the study results are truly disparate from the rest, the
additional variance components will be enormous and
the corresponding studies will have negligible weight
but more commonly the effect will be to downweight
the apparent outliers.
Results and Discussion
In this section we analyze three meta-analytic data sets,
two of which come from the Cochrane Collaboration.
The two data sets: CDP-choline for cognitive and beha-
vioural disturbances, and Fluoride toothpaste for pre-
venting dental caries have been previously analysed [4].
These provide contrasting examples. We will use the
conventional a = 0.05 in our procedure for identifying
outliers described as above but this could be altered to
reflect a priori beliefs about the possibility and impact
of the presence of outliers.
CDP-choline for cognitive and behavioural disturbances
Fioravanti and Yanagi [21] present a meta-analysis of
cytidinediphosphocholine (CDP-choline) for cognitive
and behavioural disturbances associated with chronic
cerebral disorders in the elderly. There are ten studies
for the outcome used here, memory measures, and the
yi are standardised mean differences of treatment versus
placebo with positive values of yi indicating that the
treatment is beneficial. The forest plot shows the 8th
study as an apparently obvious outlier and none of the
other results appear unusual (Figure 1). This example
provides a relatively straightforward test of our methods.
Figure 2 and Table 1 show the results for the RVSOM
analyses for the CDP-choline data set. The first plot
(a) in Figure 2 shows the estimated  j2 from the jth
RVSOM and the next two plots (b-c) show the corre-
sponding estimates of the between-study variance and
the treatment effect. The final plot (d) shows the likeli-
hood ratio test statistics from which we see that obser-
vation 8 is clearly detected as an outlier as expected; in
particular its LRT statistic is around three times the
threshold for the first order statistic. Table 1 shows
the inferences for the random effects model (M0) and
the extended RVSOM (M1; in this case, this is the same
as the RVSOM model for the 8th observation because
this was the only observation that was designated as a
potential outlier). We see that upon allowing for the
overdispersion of the 8th trial result the estimate of the
between-study variance drops to zero. The outlier is
clearly highly influential but its downweighting, which is
so huge as to be almost, but not quite, equivalent to
removing it, does not threaten the null hypothesis. The
estimate of treatment effect is approximately halved
however. Model M1 provides a suitable sensitivity analy-
sis when used in conjunction with the standard random
effects model.
Intravenous magnesium in acute myocardial infarction
These 16 trials are a well-known example where the
results of a meta-analysis were contradicted by a single
large trial [22] (trial 16). The forest plot in Figure 3
does not suggest that any of the studies are outliers but
study 16 is at best curious when compared to the other
studies and so this example presents a rather unusual
challenge to our methods.
Figure 4 show the results for the RVSOM analyses for
the intravenous magnesium in acute myocardial infarc-
tion data set. Study 16 is clearly the most influential and
although it does not provide the largest  j2 it does pro-
vide the largest likelihood ratio test and we conclude
that, although there is very weak evidence for any out-
liers in these data, it is indeed study 16, rather than
study 6 say, which provides the strongest evidence for
being an outlier. From a careful inspection of the forest
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Figure 1 Forest plot for the CDP study. Solid vertical line
represents the value of the treatment effect under a random effects
model. The centre of each circle in the confidence interval for each
study represents the treatment effect from that study. The size of
each circle is inversely proportional to the total variance under a
random effects model.
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plot, study 16 appears curious in relation to the other
studies. Our methodology has performed well, in that it
provided results which are in agreement with intuition,
by highlighting study 16 but not actually designating it
an outlier. The RVSOM for observation 16 provides
inferences that are in broad agreement with the usual
random effects analysis.
Fluoride toothpaste for preventing dental caries
Marinho et al. [23] present a meta-analysis of fluoride
toothpastes for preventing dental caries in children and
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Figure 2 RVSOM statistics plotted against study number for
the CDP study. (a) Variance shift estimates, ˆ j2 . (b) Treatment
effect estimates ˆ . (c) Random effect variance estimates ˆ 2 . (d)
Likelihood ratio test statistics for a RVSOM for study j, plotted
against study number. 95th percentile of the empirical distribution
under the null hypothesis shown for the first k order statistics for
each test: k = 1 (dotted line), k = 2 (dashed line) and k = 3 (solid
line).
Table 1 Estimated parameters for models fitted to the
CDP data: overall treatment effect (μ), variance shift
estimates for study j ( j2 ) and between-study variance
(τ2). M0: Random effects model and M1: Extended RVSOM
for study 8
Model M0 Model M1
Parameter Estimate 95% CI Estimate 95% CI
μ 0.401 (0.08;0.72) 0.191 (0.058;0.324)
τ2 0.192 - 0:000 -
82 - - 3.951 -
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Figure 3 Forest plot for the magnesium study. The centre of
each circle in the confidence interval for each study represents the
treatment effect from that study. The size of each circle is inversely
proportional to the total variance under a random effects model.
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Figure 4 RVSOM statistics plotted against study number for
the magnesium study. (a) Variance shift estimates, ˆ j2 . (b)
Treatment effect estimates ˆ . (c) Random effect variance estimates
ˆ 2 . (d) Likelihood ratio test statistics for a RVSOM for study j, plotted
against study number. 95th percentile of the empirical distribution
under the null hypothesis shown for the first k order statistics for each
test: k = 1 (dotted line), k = 2 (dashed line) and k = 3 (solid line).
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adolescents. There are 70 studies, and the outcome is
the difference between treatment and control of tooth
areas with caries; negative values of y indicate that the
treatment is beneficial. This is a large meta-analysis with
obvious outliers, but where the treatment benefit is not
in doubt, and there was no suggestion of publication
bias in the original review. The forest plot shows studies
50 and 63 as apparent outliers (Figure 5) but there are
other possibilities as well, such as study 38, so these
data presents a very considerable challenge to our meth-
ods compared to the previous examples.
Figure 6 and Table 2 show the results for the RVSOM
analyses for the flouride toothpaste data set. Studies 50
and 63 are clearly (and study 38, but to a lesser extent)
identified as outliers but other outlying results appear to
be more easily explainable by the random effects model
and do not need any additional variation to adequately
describe them. Table 2 shows that the inferences are
very robust when these three outliers are downweighted
using the extended RVSOM (which includes three w j
2 ,
j = 38, 50, 63 terms in a single model) and our findings
greatly alleviate any concerns about the potential impact
of outliers in these data. Once again, our proposed
methodology has performed well.
Conclusions
The proposed RVSOM provides a means to identify and,
if desired, downweight outliers in meta-analysis. It does
not eliminate them from the analysis however and we
consider the proposed approach preferable to simply
removing any or all apparently outlying results. We do
not however propose that our methods in any way
replace or diminish the standard random effects metho-
dology that has proved so useful, rather they are helpful
when used in conjunction with the random effects
model. We note that statistical inferences based on
−3 −2 −1 0
0
10
20
30
40
50
60
70
Measured effect
S
tu
dy
 n
um
be
r
Figure 5 Forest plot for the flouride toothpaste study. The
centre of each circle in the confidence interval for each study
represents the treatment effect from that study. The size of each
circle is inversely proportional to the total variance under a random
effects model.
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Figure 6 RVSOM statistics plotted against study number for
the flouride toothpaste study. (a) Variance shift estimates, ˆ j2 .
(b) Treatment effect estimates ˆ . (c) Random effect variance
estimates ˆ 2 . (d) Likelihood ratio test statistics for a RVSOM for
study j, plotted against study number. 95th percentile of the
empirical distribution under the null hypothesis shown for the first k
order statistics for each test: k = 1 (dotted line), k = 2 (dashed line)
and k = 3 (solid line).
Table 2 Estimated parameters for models fitted to the
for the flouride toothpaste data: overall treatment effect
(μ), variance shift estimates for study j ( j2 ) and
between-study variance (τ2). M0: Random effects model
and M1: Extended RVSOM for studies 38, 50, and 63
Model M0 Model M1
Parameter Estimate 95% CI Estimate 95% CI
μ -0.3008 (-0.33;-0.27) -0.284 (-0.32;-0.25)
τ2 0.015 - 0.009 -
382 - - 0.897 -502 - - 2.082 -632 - - 5.879 -
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modelling choices that were determined by the outcome
of statistical tests, such as ours, are open to question
and critique and partly for this reason we present our
methods only in the context of sensitivity or secondary
analyses. Our methods cannot provide reasons for any
apparent outliers but are useful when some findings
seem unaccountably unusual and their presence is a
cause for concern. We have focused our attention on
the notion of outlying trial results, rather than those
that are influential, or have high leverage, and so on,
but outliers very often exert alarming amounts of influ-
ence and these concepts are related. For the three exam-
ples considered here, the apparent outliers only had
serious implications for the CPD-choline analysis, i.e.
different estimated treatment effects result when outliers
are downweighted, and hence our methods can either
confirm or diminish any fears that inferences are driven
by a handful of unusual results.
The likelihood ratio test gives an objective measure for
detecting outliers in meta-analysis. Some may consider
this objective measure in itself useful and use this part of
the methodology alone rather than take the next step and
downweight any apparent outliers. Determining which
studies might be designated as outliers may be difficult
from the visual inspection of plots and our methods
could be used to inform this common but usually infor-
mal process. The methodology could be applied to aid
the identification of any unusual findings and shortlist
trials whose protocols and conduct should be examined
especially carefully before being entered into the analysis.
We suggest that the results from the extended
RVSOM, with inflated variances for any studies consid-
ered to be outliers, provides a useful sensitivity analysis.
If the resulting inferences for the treatment effect are
very different to those from the random effects model
then all inferences should be very cautiously interpreted.
The fixed effects version of our model (with τ2 = 0) is
computationally and conceptually simpler and might be
applied under the strong assumption of homogeneity for
the non-outlying studies. A concern here however that
the almost inevitable between-study variation will result
in more variation than the model anticipates and there-
fore the identification of ‘outliers’ that are not truly unu-
sual but rather they are due to the usual random
variation that occurs between trials. We align ourselves
with those who prefer random effects methods for meta-
analysis but appreciate the arguments made by those
whose opinions differ to ours. We have built our model
on the standard random effects model which assumes
within and between-study normality. If some studies are
small and their within-study normal approximations are
not accurate then some apparent outliers may be due to
this assumption and this possibility should be considered.
Non-normal between-study distributions have also been
used in meta-analysis [4,24]. It is interesting that our
extended RVSOM produced very similar results for our
first and third examples as the heavy tailed distributions
for the random effect adopted by Baker and Jackson [4].
Both the extended RVSOM and these heavy tailed ran-
dom effects serve to down-weight the outliers so this
might be expected to be the case more generally. How-
ever the methods proposed here avoid integrating out
unusual random effects and MCMC methods [24] and
retain all the advantages of working with data that are
assumed to be normally distributed.
The RVSOM model is not especially appropriate if
there are many apparent outliers or the collection of
trial results are truly unusual; it is not helpful or mean-
ingful to designate a large proportion of the studies as
outliers. In such instances many would balk at the possi-
bility of meta-analysis altogether but heavy tailed or less
usual models for the random effect may be useful in
such instances, as shown by Baker and Jackson [4].
Our procedure for the computation of thresholds for
the likelihood ratio test statistics makes our proposal
quite computationally intensive but in the current cli-
mate this presents little difficulty. More computationally
intensive methods involving bootstrapping and permuta-
tion tests are becoming more common proposals in
meta-analysis however and we anticipate that this trend
will continue.
Appendix: Computations
The analysis for the three examples given in the manu-
script were conducted using Genstat [11] but full R [12]
code is available at http://www.mrc-bsu.cam.ac.uk/Soft-
ware/download.html#RPackages.
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